RECRUITING

Muscle Blood Flow Regulation in HFpEF

Talk to us

Conditions

HFpEFMuscle Blood FlowExercise Tolerance

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System. Exercise intolerance is a common complication experienced by patients with HFpEF, perpetuating physical inactivity and accelerating disease progression. This research proposal aims to elucidate mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF compared with healthy controls as well as following 8 weeks of exercise training in patients with HFpEF only.

Official Title

Mechanisms of Impaired Skeletal Muscle Blood Flow and Exercise Intolerance in Veterans With Heart Failure With Preserved Ejection Fraction: Efficacy of Knee Extensor Training

Quick Facts

Study Start:2022-07-01
Study Completion:2028-02-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05115890

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older and able to give written informed consent
  2. * New York Heart Association (NYHA) functional class II or III
  3. * Left Ventricular Ejection Fraction (LVEF) \> 50%
  4. * Plasma Brain Natriuretic Peptide (BNP) \>200 pg/mL or NT-proBNP 400 pg/mL at enrollment
  1. * Prior EF of \<50%.
  2. * NYHA Class IV or HF that cannot be stabilized on optimized pharmacotherapy
  3. * Acute coronary syndrome, infiltrative cardiomyopathy, or myocarditis
  4. * Patients with HFpEF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction)
  5. * Orthopedic limitations that would prohibit knee-extensor exercise
  6. * Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT
  7. * Women who are pregnant or may become pregnant, but the typical age of female patients with HFpEF will be postmenopausal
  8. * Current smokers

Contacts and Locations

Study Contact

P Jon White, MD
CONTACT
(801) 582-1565
Paul.White2@va.gov

Principal Investigator

Kanokwan Bunsawat, PhD
PRINCIPAL_INVESTIGATOR
VA Salt Lake City Health Care System, Salt Lake City, UT

Study Locations (Sites)

VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001
United States

Collaborators and Investigators

Sponsor: VA Office of Research and Development

  • Kanokwan Bunsawat, PhD, PRINCIPAL_INVESTIGATOR, VA Salt Lake City Health Care System, Salt Lake City, UT

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-01
Study Completion Date2028-02-29

Study Record Updates

Study Start Date2022-07-01
Study Completion Date2028-02-29

Terms related to this study

Keywords Provided by Researchers

  • HFpEF
  • Muscle Blood Flow
  • Exercise Tolerance

Additional Relevant MeSH Terms

  • HFpEF